ArticleESMO gastrointestinal oncology2024

PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer.

T Sakakida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.